OncRef

Clinical Trial: NCT00846742

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:St. Jude Children's Research Hospital
Information Provided By:St. Jude Children's Research Hospital
Last Update Posted:2026-05-26

Study Overview

Brief Summary

This phase II trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with favorable-risk Hodgkin lymphoma. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, mechlorethamine hydrochloride, vincristine sulfate, bleomycin, etoposide, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells for those patients that still had residual cancer at the end of chemotherapy. Giving combination chemotherapy with radiation therapy may kill more cancer cells and allow doctors to save the part of the body where the cancer started.

Official Title

Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma

Conditions

Hodgkin Lymphoma

Intervention / Treatment

  • Drug: Stanford V Chemotherapy
  • Radiation: Radiation Therapy

Other Study ID Numbers

  • HOD08
  • NCI-2009-01138

Start Date (Actual)

2009-06-05

Primary Completion Date (Actual)

2019-01-11

Study Completion Date (Estimated)

2028-10

Enrollment (Actual)

88

Study Type

Interventional

Phase

Phase 2